Skip to main content Accessibility help
×
Home

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine

  • Claudio N. Soares (a1) (a2), Min Zhang (a3) and Matthieu Boucher (a4)

Abstract

Objective

This post-hoc pooled analysis evaluated categorical change in functional impairment in patients with major depressive disorder (MDD) treated with desvenlafaxine versus placebo and examined whether early improvement in functioning predicted functional outcomes at study endpoint.

Methods

Data were pooled from eight randomized, double-blind, placebo-controlled studies of desvenlafaxine for the treatment of MDD, including adults who were randomly assigned to receive desvenlafaxine 50 or 100 mg/d or placebo (N=3,384). Shift tables were generated for categorical changes in functional impairment from baseline based on Sheehan Disability Scale (SDS) subscale scores. The categories were none/mild (0–3), moderate (4–6), and marked/extreme (7–10). Treatment comparisons for prespecified shifts of interest and predictive value of week 2 or 4 improvement in SDS subscale scores for functional outcome at week 8 were assessed using logistic regression.

Results

Greater proportions of patients receiving desvenlafaxine 50 and 100 mg achieved improvement from baseline to week 8 for each prespecified shift endpoint versus placebo (all p ≤ 0.02). Early improvement in SDS subscale scores was a statistically significant predictor of functional outcome at week 8, both overall and for each treatment group (all p<0.0001).

Conclusions

Treatment with desvenlafaxine 50 or 100 mg/d led to significantly greater categorical improvement in functional impairment versus placebo, and improvement in SDS subscale scores significantly predicted functional outcome. Monitoring patient progress early in the course of antidepressant treatment using a functional assessment such as the SDS may help clinicians determine whether or not treatment adjustments are needed.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine
      Available formats
      ×

Copyright

The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/4.0/>. The written permission of Cambridge University Press must be obtained for commercial re-use.

Corresponding author

*Address for correspondence: Claudio N. Soares, Professor of Psychiatry, Queen’s University School of Medicine, 76 Stuart Street, Burr 4, Kingston, Ontario, Canada K7L 2V7. (Email: c.soares@queensu.ca)

References

Hide All
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association; 2013: 160168.
2. Lerner, D, Adler, DA, Chang, H, et al. Unemployment, job retention, and productivity loss among employees with depression. Psychiatr Serv. 2004; 55(12): 13711378.
3. Jain, G, Roy, A, Harikrishnan, V, Yu, S, Dabbous, O, Lawrence, C. Patient-reported depression severity measured by the PHQ–9 and impact on work productivity: results from a survey of full-time employees in the United States. J Occup Environ Med. 2013; 55(3): 252258.
4. Beck, A, Crain, LA, Solberg, LI, et al. The effect of depression treatment on work productivity. Am J Manag Care. 2014; 20(8): e294e301.
5. Asami, Y, Goren, A, Okumura, Y. Work productivity loss with depression, diagnosed and undiagnosed, among workers in an internet-based survey conducted in Japan. J Occup Environ Med. 2015; 57(1): 105110.
6. Kessler, RC, Berglund, P, Demler, O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS–R). JAMA.. 2003; 289(23): 30953105.
7. Guico-Pabia, CJ, Fayyad, RS, Soares, CN. Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis. Int Clin Psychopharmacol. 2012; 27(1): 17.
8. Dennehy, EB, Marangell, LB, Martinez, J, Balasubramani, GK, Wisniewski, SR. Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR*D. J Psychiatr Pract. 2014; 20(3): 178187.
9. Sheehan, DV, Chokka, PR, Granger, RE, Walton, RJ, Raskin, J, Sagman, D. Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine. Hum Psychopharmacol. 2011; 26(3): 242251.
10. van der Voort, TY, Seldenrijk, A, van, MB, et al. Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder. J Clin Psychiatry. 2015; 76(6): e809e814.
11. Rush, AJ. Distinguishing functional from syndromal recovery: implications for clinical care and research. J Clin Psychiatry. 2015; 76(6): e832e834.
12. Zajecka, J, Kornstein, SG, Blier, P. Residual symptoms in major depressive disorder: prevalence, effects, and management. J Clin Psychiatry. 2013; 74(4): 407414.
13. Gelenberg, AJ, Freeman, MP, Markowitz, JC, et al. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Arlington, VA: American Psychiatric Association http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed September 7, 2017.
14. Lam, RW, McIntosh, D, Wang, J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder, section 1: disease burden and principles of care. Can J Psychiatry. 2016; 61(9): 510523.
15. Habert, J, Katzman, MA, Oluboka, OJ, et al. Functional recovery in major depressive disorder: focus on early optimized treatment. Prim Care Companion CNS Disord. 2016; 18(5): http://www.psychiatrist.com/PCC/article/Pages/2016/v18n05/15r01926.aspx. Accessed September 7, 2017.
16. Lam, RW, Filteau, MJ, Milev, R. Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord. 2011; 132(Suppl 1): S9S13.
17. Sheehan, DV, Nakagome, K, Asami, Y, Pappadopulos, EA, Boucher, M. Restoring function in major depressive disorder: a systematic review. J Affect Disord. 2016; 215: 299313.
18. Sheehan, DV, Harnett-Sheehan, K, Raj, BA. The measurement of disability. Int Clin Psychopharmacol. 1996; 11(Suppl 3): 8995.
19. Sheehan, KH, Sheehan, DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008; 23(2): 7083.
20. Soares, CN, Kornstein, SG, Thase, ME, Jiang, Q, Guico-Pabia, CJ. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry. 2009; 70(10): 13651371.
21. Oakes, TM, Myers, AL, Marangell, LB, et al. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol. Hum Psychopharmacol. 2012; 27(1): 4756.
22. Sambunaris, A, Gommoll, C, Chen, C, Greenberg, WM. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int Clin Psychopharmacol. 2014; 29(4): 197205.
23. Soares, CN, Endicott, J, Boucher, M, Fayyad, RS, Guico-Pabia, CJ. Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder. CNS Spectr.. 2014; 19(6): 519527.
24. Mancini, M, Sheehan, DV, Demyttenaere, K, et al. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. Int Clin Psychopharmacol. 2012; 27(6): 298309.
25. Cutler, AJ, Gommoll, CP, Chen, C, Greenberg, WM, Ruth, A. Levomilnacipran extended-release treatment in patients with major depressive disorder: improvements in functional impairment categories. Prim Care Companion CNS Disord. 2015; 17(3): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578909/. Accessed September 7, 2017.
26. Boyer, P, Montgomery, S, Lepola, U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008; 23(5): 243253.
27. Iwata, N, Tourian, KA, Hwang, E, Mele, L, Vialet, C. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013; 19(1): 514.
28. Clayton, A, Tourian, KA, Focht, K, Hwang, E, Cheng, RF, Thase, ME. Desvenlafaxine 50- and 100-mg/d vs. placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry. 2015; 76(5): 562–529.
29. Rosenthal, JZ, Boyer, P, Vialet, C, Hwang, E, Tourian, KA. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. J Clin Psychiatry. 2013; 74(2): 158166.
30. Pristiq package insert. Philadelphia: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer; 2016.
31. Pristiq product monograph. Kirkland, Quebec: Pfizer Canada; 2016.
32. DeMartinis, NA, Yeung, PP, Entsuah, R, Manley, AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007; 68(5): 677688.
33. Liebowitz, MR, Manley, AL, Padmanabhan, SK, Ganguly, R, Tummala, R, Tourian, KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008; 24(7): 18771890.
34. Tourian, KA, Padmanabhan, SK, Groark, J, Brisard, C, Farrington, D. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009; 31(Pt 1): 14051423.
35. Liebowitz, MR, Tourian, KA, Hwang, E, Mele, L. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major depressive disorder. BMC Psychiatry. 2013; 13(1): 94 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763843/. Accessed September 7, 2017.
36. Clayton, AH, Kornstein, SG, Dunlop, BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2013; 74(10): 10101017.
37. Dunlop, BW, Reddy, S, Yang, L, Lubaczewski, S, Focht, K, Guico-Pabia, CJ. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011; 31(5): 569576.
38. Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 5662.
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Publishing; 1994.
40. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision , 4th ed. Washington, DC: American Psychiatric Publishing; 2000.
41. Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382389.
42. Gallop, RJ. Determination and interpretation of the OOP for ROC’s with PROC LOGISTIC. Baltimore: NorthEast SAS Users Group; 2001. http://www.lexjansen.com/nesug/nesug01/st/st9006r.pdf. Accessed September 7, 2017.
43. Tohen, M, Case, M, Trivedi, MH, Thase, ME, Burke, SJ, Durell, TM. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 2010; 71(4): 451462.
44. Soares, CN, Fayyad, RS, Guico-Pabia, CJ. Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. J Clin Psychopharmacol. 2014; 34(1): 5765.
45. Lam, RW, Endicott, J, Hsu, MA, Fayyad, R, Guico-Pabia, C, Boucher, M. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. Int Clin Psychopharmacol. 2014; 29(5): 239251.

Keywords

Type Description Title
WORD
Supplementary materials

Soares et al supplementary material
Appendix Table 1

 Word (31 KB)
31 KB
WORD
Supplementary materials

Soares et al supplementary material
Appendix Table 2

 Word (21 KB)
21 KB
WORD
Supplementary materials

Soares et al supplementary material
Appendix Table 3

 Word (23 KB)
23 KB
WORD
Supplementary materials

Soares et al supplementary material
Figures S1-S2

 Word (123 KB)
123 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed